Jane Wan

 jayk7/Getty Images

Chinese healthcare reforms may be a double-edged sword for foreign companies.

Brunei harnesses its rich biodiversity and the growing halal market in a bid to develop its pharmaceutical sector.

China's regulatory and compliance environment is set to change as the government declares a crackdown on bribery scandals.

The rising cost of drug development and the decreasing proportion of drug-naive population in the US and European markets are driving international pharmaceutical companies to consider emerging markets as a location to conduct their clinical trials. Asia stands out among the emerging markets given its double-digit growth rates.

Foreign companies zero in on Myanmar with the hope of securing a foothold in its pharmaceutical market.

Industry players brace themselves to face challenges as India's new drug-pricing policy kicks in full gear.

The Taiwanese government engages in regulatory science in a move to boost its pharmaceutical sector.

The Thai government is ramping up efforts to promote and develop the biotechnology sector in a bid to enhance its global competitiveness.

India's biopharmaceutical industry is valued at $2 billion a year with 20 companies producing biosimilars and 50 products available in the domestic market.